A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura
A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura
The primary objective of this study was to assess the long term safety of fostamatinib in subjects with persistent/chronic ITP
Inclusion Criteria:
Exclusion Criteria:
Sofia, BG 1756, Bulgaria
Ostrava-Poruba, 708 52, Czechia
Udine, 33100, Italy
Krakow, 31-501, Poland